Literature DB >> 20733415

A comparison of thoracolumbosacral orthoses and SpineCor treatment of adolescent idiopathic scoliosis patients using the Scoliosis Research Society standardized criteria.

Steven R Gammon1, Charles T Mehlman, Winston Chan, Jonathan Heifetz, Gregory Durrett, Eric J Wall.   

Abstract

BACKGROUND: SpineCor is a relatively new bracing system that uses dynamic bracing concepts in the treatment of adolescent idiopathic scoliosis (AIS). Limited data are available regarding its effectiveness. This study compared treatment outcomes of 2 groups of AIS patients treated via either a conventional rigid thoracolumbosacral orthoses (TLSO) or a SpineCor nonrigid orthosis.
METHODS: We identified 2 scoliosis patient cohorts: 35 patients treated with a TLSO and 32 patients treated with a SpineCor orthosis. All patients included in these groups conformed with the Scoliosis Research Society (SRS) standardized criteria for AIS bracing: (1) Risser < or =2, (2) curve magnitude 25 to 40 degrees, (3) age > or =10 years. Outcomes were SRS standardized with failure being defined as curve progression > or =6 degrees, or ever exceeding 45 degrees, or having surgery recommended before skeletal maturity. All patients were followed through the completion of brace treatment or attainment of other treatment end points. The Yates corrected chi test and unpaired t test were used for data analysis.
RESULTS: The 35 patients (32 girls, 3 boys) in the TLSO group had an average age of 13 years (range: 11.1-16.8) and an average primary curve magnitude of 33 degrees (range: 25-40 degrees). Follow-up averaged 2 years (range: 8-61 m) from the beginning of brace treatment. The 32 patients (28 girls, 4 boys) in the SpineCor group had an average age of 13 years (range: 11-15.2) and an average primary curve magnitude of 31 degrees (range: 25-40 degrees). Follow-up for this group averaged 2 years and 6 months (range: 13-73 mo) from the beginning of brace treatment. No significant difference (P=0.75) was found using the more strict outcome measure (< or =5-degree curve progression) as the success rates were 60% (21/35) for TLSO and 53% (17/32) for SpineCor. Similarly, no significant difference (P=0.62) was found using the more liberal outcome measure (never reached 45 degrees) as the success rates were 80% (28/35) for TLSO and 72% (23/32) for SpineCor.
CONCLUSIONS: We were unable to identify any significant differences in brace treatment outcomes when comparing TLSO and SpineCor treated patients.

Entities:  

Mesh:

Year:  2010        PMID: 20733415     DOI: 10.1097/BPO.0b013e3181e4f761

Source DB:  PubMed          Journal:  J Pediatr Orthop        ISSN: 0271-6798            Impact factor:   2.324


  15 in total

1.  Design of the Bracing in Adolescent Idiopathic Scoliosis Trial (BrAIST).

Authors:  Stuart L Weinstein; Lori A Dolan; James G Wright; Matthew B Dobbs
Journal:  Spine (Phila Pa 1976)       Date:  2013-10-01       Impact factor: 3.468

2.  Factors associated with the success of the Rigo System Chêneau brace in treating mild to moderate adolescent idiopathic scoliosis.

Authors:  Dror Ovadia; Sharon Eylon; Avraham Mashiah; Shlomo Wientroub; Eduard David Lebel
Journal:  J Child Orthop       Date:  2012-08-14       Impact factor: 1.548

3.  A prospective randomized controlled study on the treatment outcome of SpineCor brace versus rigid brace for adolescent idiopathic scoliosis with follow-up according to the SRS standardized criteria.

Authors:  Jing Guo; Tsz Ping Lam; Man Sang Wong; Bobby Kin Wah Ng; Kwong Man Lee; King Lok Liu; Lik Hang Hung; Ajax Hong Yin Lau; Sai Wing Sin; Wing Kwan Kwok; Fiona Wai Ping Yu; Yong Qiu; Jack Chun Yiu Cheng
Journal:  Eur Spine J       Date:  2013-12-31       Impact factor: 3.134

Review 4.  2016 SOSORT guidelines: orthopaedic and rehabilitation treatment of idiopathic scoliosis during growth.

Authors:  Stefano Negrini; Sabrina Donzelli; Angelo Gabriele Aulisa; Dariusz Czaprowski; Sanja Schreiber; Jean Claude de Mauroy; Helmut Diers; Theodoros B Grivas; Patrick Knott; Tomasz Kotwicki; Andrea Lebel; Cindy Marti; Toru Maruyama; Joe O'Brien; Nigel Price; Eric Parent; Manuel Rigo; Michele Romano; Luke Stikeleather; James Wynne; Fabio Zaina
Journal:  Scoliosis Spinal Disord       Date:  2018-01-10

5.  Soft braces in the treatment of Adolescent Idiopathic Scoliosis (AIS) - Review of the literature and description of a new approach.

Authors:  Hans-Rudolf Weiss; Mario Werkmann
Journal:  Scoliosis       Date:  2012-05-28

6.  Team care to cure adolescents with braces (avoiding low quality of life, pain and bad compliance): a case-control retrospective study. 2011 SOSORT Award winner.

Authors:  Marta Tavernaro; Anna Pellegrini; Fabrizio Tessadri; Fabio Zaina; Andrea Zonta; Stefano Negrini
Journal:  Scoliosis       Date:  2012-09-20

7.  In defense of adolescents: They really do use braces for the hours prescribed, if good help is provided. Results from a prospective everyday clinic cohort using thermobrace.

Authors:  Sabrina Donzelli; Fabio Zaina; Stefano Negrini
Journal:  Scoliosis       Date:  2012-05-31

8.  2011 SOSORT guidelines: Orthopaedic and Rehabilitation treatment of idiopathic scoliosis during growth.

Authors:  Stefano Negrini; Angelo G Aulisa; Lorenzo Aulisa; Alin B Circo; Jean Claude de Mauroy; Jacek Durmala; Theodoros B Grivas; Patrick Knott; Tomasz Kotwicki; Toru Maruyama; Silvia Minozzi; Joseph P O'Brien; Dimitris Papadopoulos; Manuel Rigo; Charles H Rivard; Michele Romano; James H Wynne; Monica Villagrasa; Hans-Rudolf Weiss; Fabio Zaina
Journal:  Scoliosis       Date:  2012-01-20

9.  Effectiveness of brace treatment for adolescent idiopathic scoliosis.

Authors:  Toru Maruyama; Yosuke Kobayashi; Makoto Miura; Yusuke Nakao
Journal:  Scoliosis       Date:  2015-02-11

10.  The effectiveness of combined bracing and exercise in adolescent idiopathic scoliosis based on SRS and SOSORT criteria: a prospective study.

Authors:  Stefano Negrini; Sabrina Donzelli; Monia Lusini; Salvatore Minnella; Fabio Zaina
Journal:  BMC Musculoskelet Disord       Date:  2014-08-06       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.